(EBMT	

Treatment Type	Other
Treatment Type	Other

Treatment Date _ _ _ / _ / _ _ (YYY//////DD)

TREATMENT NON – HCT/CT/GT/IST			
(Malignant disorders and Immunoglobulin-related amyloidosis(AL))			
HCT/CT/GT-related forms. Treatme extended dataset.	en (conditioning/lymphodepletion) and (nt for GvHD and complications should		
Date treatment started: / _	1(YYYY/MM/DD)		
Diagnosis for which this treatme	nt was given:		
Line of treatment: (nur A line of treatment covers all cycles same disease status of the patient	s of the same drugs/regimen given in t	he same period with the same re	eason, and within the
Reason for this line of treatment	:		
	laintenance / preventive treatment: Consolidation Dther; specify:	Type of relapse prevention:	 MRD negative MRD positive MRD unknown
	CHEMOTHERAPY / DRUG	REGIMEN	
Chemotherapy/Drugs: 🗌 No	Yes Unknown		
If patient received chemothe (Do not report each drug start			
	(YYYY/MM/DD) Unknown emo/drugs for this line of treatment)		
Treatment stopped: No	End date: I I (YYYY/ <i>N</i> (report latest end date of chemo/dru		
	Reason for treatment withdrawal: (for Chronic Lymphocytic Leukaemia	only) Planned withdrawal Toxicity Progression or insuffic	sient response
		☐ Other reason; specify	·
Unkno	own		



Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

CHEMOTHERAPY / DRUG REGIMEN

Chemo/Drug regimen*:	
Extended dataset	
(Acute Leukaemia and Lymphoma only) Number of cycles: Unknown	(Acute Leukaemia only) Number of days per cycle: Unknown
	Daily dose: Unknown
	Units: mg/m ² mg/kg mg mg/mL
Chemo/Drug regimen*:	
Extended dataset	
(Acute Leukaemia and Lymphoma only) Number of cycles: □ Unknown	(<i>Acute Leukaemia only</i>) Number of days per cycle: Unknown
	Daily dose: Unknown
	Units: mg/m ² mg/kg mg mg/mL
Chemo/Drug regimen*:	
Extended dataset	
(Acute Leukaemia and Lymphoma only) Number of cycles: Unknown	(Acute Leukaemia only) Number of days per cycle: Unknown
	Daily dose: Unknown
	Units: mg/m ² mg/kg mg mg/mL

*Please consult the **LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS** on the EBMT website for drugs/regimens names.

Copy and fill-in this page (chemotherapy / drug regimen) as often as necessary within the same line of treatment.

Extended dataset			
Intrathecal therapy: (Acute Leukaemia only)	🗌 No	🗌 Yes	Unknown

EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN):	Treatment Type 🔲 Other			
Patient Number in EBMT Registry:	 Treatment Date / _ / (YYYY/MM/DD)			
INTERVENTIO	NS			
Radiotherapy: 🗌 No 📄 Yes 📄 Unknown				
If patient received radiotherapy incl. irradiation: Start date: I _ I _ (YYYY/MM/DD) Unknown				
Treatment stopped: No Yes; End date: I Unknown	/MM/DD) 🔲 Unknown			
Splenic irradiation: No Yes Unknown (for Myeloproliferative neoplasms only) If patient received splenic irradiation: Total prescribed radiation dose as per protocol: Gy Unknown				
Number of fractions: Unknown				
Number of radiation days: 🔲 Unknown				
Surgery: 🗌 No 📄 Yes 📄 Unknown				
If patient underwent surgery: Date: / _ / _ (YYYY/MM/DD) Unknown				
Surgery type: Splenectomy Other; specify Unknown Copy and fill-in this section as often as necessary within the same line of treatment.				
RESPONSE TO THIS LINE OF TREATMENT (Disease Specific)				
Complete only one section with the main indication diagnosis for which tr	reatment was given.			
Response assessment date:/_/ _/ _/ (YYYY/MM/DD) Unki	nown			
ACUTE LEUKAEMIAS	Go to page 4			
CHRONIC LEUKAEMIAS	Go to page 4			
PLASMA CELL NEOPLASMS (PCN)	Go to page 4			
MYELOPROLIFERATIVE NEOPLASMS (MPN)	Go to page 5			
MYELODYSPLASTIC NEOPLASMS (MDS)	Go to page 5			
MDS / MPN OVERLAP SYNDROMES	Go to page 5			
LYMPHOMAS	Go to page 6			

SOLID TUMOURS

OTHER DIAGNOSIS

Go to page 6

Go to page 6



Treatment Date _ _ _ / _ / _ (YYY/MM/DD)

RESPONSE TO THIS LINE OF TREATMENT

Complete only one section with the main indication diagnosis for which treatment was given.

Acute leukaemias (AML, PLN, Other)

Complete remission (CR)	
Not in complete remission	
Not evaluated	

Chronic leukaemias (CML, CLL, PLL, Other)

<u>Chronic Myeloid Leukaemia (CML):</u>				
Chronic phase (CP); Number: 1 st 2 ^r	nd 🗌 3rd	or higher 🗌] Unknown	
Haematological remission	on: 🔲 No	🗌 Yes	Not evaluated	Unknown
Cytogenetic remission:	🗌 No	🗌 Yes	☐ Not evaluated	Unknown
Molecular remission:	🗌 No	🗌 Yes	☐ Not evaluated	Unknown
Accelerated phase; Number: 1 st 2 nd	☐ 3 rd 0I	higher	Unknown	
Blast crisis; Number: 1 st 2 nd 3 ^{rc}	or higher		n	
□ Not evaluated				
Unknown				

Chronic Lymphocytic Leukaemia (CLL), Prolymphocytic Leukaemia (PLL) and other chronic leukaemias:

Complete remission (CR)		
Partial remission (PR)		
Progression: Resistant to last regimen	Sensitive to last regimen	🔲 Unknown
Stable disease (no change, no response/loss o	f response)	
☐ Not evaluated		
Unknown		

Plasma cell neoplasms (PCN)

Complete remission (CR)	Number: 🔲 1st	
Stringent complete remission (sCR)		
Ury good partial remission (VGPR)	☐ 3rd or higher	
Partial remission (PR)	Unknown	
□ Relapse		
Progression		
Stable disease (no change, no response/loss of response)		
Not evaluated		
Unknown		

For AL, CLL and PCN proceed to next page



Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

RESPONSE TO THIS LINE OF TREATMENT

Complete only for AL, CLL and PCN	,,
Leukaemias (AL, CLL) and PCN	(complete only for patient in CR or sCR)
Minimal residual disease (MRD): Negative Positive Not evaluated Unknown 	
Date MRD status evaluated:	//(<i>YYYY/MM/DD</i>)
Sensitivity of MRD assay:	Method used: (select all that apply) PCR Flow cytometry NGS Other; specify: Unknown

Complete only one section with the main indication diagnosis for which treatment was given.

Myeloproliferative neoplasms (MPN), Myelodysplastic neoplasms (MDS), MDS/MPN overlap syndromes

Complete remission (CR)	Number: 1st
	☐ 2nd
	3rd or higher
Improvement but no CR	
Primary refractory phase (no change)	
Relapse	Number: 1st
	☐ 2nd
	3rd or higher
Progression/Worsening	
□ Not evaluated	
Unknown	



Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

RESPONSE TO THIS LINE OF TREATMENT continued

Complete only one section with the main indication diagnosis for which treatment was given.

Lymphomas

Chemorefractory relapse or progression, including prir	mary refractory disease	
Complete remission (CR): Confirmed	Unconfirmed (CRU*)	Unknown
Partial remission (PR)		
Stable disease (no change, no response/loss of response)		
Untreated relapse (from a previous CR) or progression (from a previous PR)		
Not evaluated		
Unknown		

* CRU: Complete response with persistent scan abnormalities of unknown significance

Solid tumours

Complete remission (CR): Confirmed Unconfirmed Unknown	
First Partial remission	
Partial remission (PR)	
Progressive disease	
Relapse: Resistant Sensitive Unknown	
Stable disease (no change, no response/loss of response)	
Not evaluated	

Other diagnosis

□ No evidence of disease
No response
U Worse
Not evaluated